Technological advances in Radioimmunotherapy

被引:21
作者
Dearling, J. L. J. [1 ]
Pedley, R. B. [1 ]
机构
[1] UCL, Dept Oncol, Canc Res UK Targeting & Imaging Grp, London, England
关键词
antibody engineering; combination therapies; radioimmunotherapy; radionuclides; targeted radiotherapy;
D O I
10.1016/j.clon.2007.03.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radioimmunotherapy (RIT) is a method of selectively delivering radionuclides with toxic emissions to cancer cells, while reducing the dose to normal tissues. Although primary tumours can often be treated successfully with external beam radiotherapy or surgery, metastases often escape detection and treatment, leading to therapy failure, and these can be treated with systemic targeted therapies such as RIT. This review describes more recent developments in the field, including both technological developments from the laboratory and increasingly encouraging findings from clinical studies.
引用
收藏
页码:457 / 469
页数:13
相关论文
共 139 条
[1]  
Adams GP, 2001, CANCER RES, V61, P4750
[2]   Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules [J].
Adams, GP ;
Shaller, CC ;
Chappell, LL ;
Wu, C ;
Horak, EM ;
Simmons, HH ;
Litwin, S ;
Marks, JD ;
Weiner, LM ;
Brechbiel, MW .
NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (04) :339-346
[3]   Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers [J].
Adams, GP ;
Tai, MS ;
McCartney, JE ;
Marks, JD ;
Stafford, WF ;
Houston, LL ;
Huston, JS ;
Weiner, LM .
CLINICAL CANCER RESEARCH, 2006, 12 (05) :1599-1605
[4]   A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice [J].
Adams, GP ;
Shaller, CC ;
Dadachova, E ;
Simmons, HH ;
Horak, EM ;
Tesfaye, A ;
Klein-Szanto, AJP ;
Marks, JD ;
Brechbiel, MW ;
Weiner, LM .
CANCER RESEARCH, 2004, 64 (17) :6200-6206
[5]  
Adams GP, 1998, CANCER RES, V58, P485
[6]   In vitro characterization of 211At-labeled antibody A33 -: a potential therapeutic agent against metastatic colorectal carcinoma [J].
Almqvist, Y ;
Orlova, A ;
Sjöström, A ;
Jensen, HJ ;
Lundqvist, H ;
Sundin, A ;
Tolmachev, V .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2005, 20 (05) :514-523
[7]  
Alvarez RD, 2002, CLIN CANCER RES, V8, P2806
[8]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[9]  
Bartolomei M, 2004, Q J NUCL MED MOL IM, V48, P220
[10]  
BEAUMIER PL, 1991, CANCER RES, V51, P676